ArticleSignal transduction and targeted therapy2026

Dual epitope anti-LILRB4 synthetic T-cell receptor and antigen receptor (STAR)-T-cell therapy for relapsed/refractory acute myeloid leukemia.

Meng Lv et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.